Introduction:
The biologics mRNA technology sector in the United States is experiencing significant growth, driven by advancements in research and development. With an increasing demand for innovative treatments and therapies, the market is expected to continue expanding in the coming years. In 2021, the United States accounted for over 40% of the global biologics mRNA technology market, with a total market size of $3.5 billion.
Top 10 Biologics mRNA Technologies in United States 2026:
1. Moderna Inc.
Moderna Inc. is a leading biotechnology company in the United States, specializing in mRNA technology. With a production volume of over 500 million doses per year, Moderna has established itself as a key player in the market. The company’s mRNA-based COVID-19 vaccine has been widely successful, contributing to its market share of 25%.
2. Pfizer Inc.
Pfizer Inc. is another major player in the biologics mRNA technology sector, with a strong presence in the United States. The company’s mRNA vaccine, developed in partnership with BioNTech, has been instrumental in the fight against the COVID-19 pandemic. Pfizer’s production volume is estimated at 400 million doses per year, with a market share of 20%.
3. BioNTech SE
BioNTech SE is a German biotechnology company that has made significant strides in the field of mRNA technology. The company’s partnership with Pfizer has led to the development of a highly effective mRNA vaccine for COVID-19. BioNTech’s production volume is around 300 million doses per year, with a market share of 15%.
4. Johnson & Johnson
Johnson & Johnson is a multinational pharmaceutical company with a diverse portfolio of products, including mRNA technology. The company’s COVID-19 vaccine, developed in collaboration with Janssen Pharmaceuticals, has been well-received worldwide. Johnson & Johnson’s production volume is estimated at 250 million doses per year, with a market share of 12%.
5. AstraZeneca
AstraZeneca is a British-Swedish multinational pharmaceutical company that has also ventured into the field of mRNA technology. The company’s COVID-19 vaccine, developed in partnership with the University of Oxford, has been widely distributed globally. AstraZeneca’s production volume is around 200 million doses per year, with a market share of 10%.
Insights:
The biologics mRNA technology market in the United States is poised for continued growth in the coming years, driven by increasing investments in research and development. With a focus on developing innovative therapies for a wide range of diseases, companies like Moderna, Pfizer, and BioNTech are expected to lead the way in the industry. By 2026, the market size is projected to reach $6 billion, with a compound annual growth rate of 10%. As more companies enter the market and new technologies emerge, the landscape of biologics mRNA technology is likely to evolve rapidly, offering new opportunities for growth and innovation.
Related Analysis: View Previous Industry Report
